Study of severe HPV disease and why it keeps coming back
Part of Cancer, Infections clinical trials.
This study follows people with severe or hard-to-treat HPV-related conditions (and some closely related partners/household contacts) to learn how the virus causes illness and how the immune system responds. It may help doctors better predict who will develop severe disease and guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 3 or older (unless you’re a partner/household contact—then you must be 18+).
- You (or a parent/guardian if under 18) can agree to join the study.
- You must be willing to have genetic testing done on samples collected from you.
- If you have HPV-related disease: you need severe HPV problems that keep returning or don’t respond to standard treatments, or HPV-related squamous cell cancer.
- If you’re a control (relative/household contact/sexual partner): you must not have evidence of HPV disease that would qualify you as an “affected” participant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a detailed DNA test to look for high-risk HPV in people with long-lasting (chronic) infection after treatment or with return of abnormal cells. It may help improve how clinicians monitor high-risk HPV and decide next steps.
This trial tests two experimental vaccines to boost the immune system against HPV 16. Healthy relatives of patients with HPV 16 cancer receive the vaccines, then donate blood cells for research.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This study looks at why some people have severe or unusual viral infections, even when they do not have a known immune problem. It collects blood and tissue samples to better understand possible inherited immune issues and may help future diagnosis and treatment.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
This study looks at follow-up care for anal (rear passage) HPV risk in adults who previously had high-risk HPV–related gynecologic changes. It aims to better track disease that may be related to HPV and possibly help guide future monitoring.
Hear when a new Human Papillomavirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.